{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:47:04Z","timestamp":1778881624845,"version":"3.51.4"},"reference-count":28,"publisher":"Tech Science Press","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["oncol res"],"published-print":{"date-parts":[[2016,1,21]]},"abstract":"<jats:p>Efficacy and safety of dasatinib in chronic phase (CP) chronic myelogenous leukemia (CML) patients has been well established. Initially approved dose and schedule of 70 mg twice daily has been changed to 100 mg once daily after demonstration of the same efficacy with less toxicity.\n Some patients require significant dose reductions to enable continued treatment with dasatinib. Even at a dose of 80 mg once daily, several patients may require further dose reductions due to substantial toxicity while maintaining good control of their disease. We report two CP-CML patients\n achieving and maintaining major molecular responses while on very low doses of dasatinib, ultimately achieving undetectable levels of BCR-ABL fusion transcript in their peripheral blood. Observations of several CP-CML cases responding remarkably well to dasatinib despite very low dose and\n frequent dose interruptions challenge our current understanding and the accuracy of the data regarding the optimum dose and schedule of this drug. In selected intolerant patients, low-dose dasatinib therapy may be a safe and effective alternative treatment option before a treatment discontinuation or change considered.<\/jats:p>","DOI":"10.3727\/096504015x14452563485986","type":"journal-article","created":{"date-parts":[[2016,1,16]],"date-time":"2016-01-16T19:54:38Z","timestamp":1452974078000},"page":"1-5","source":"Crossref","is-referenced-by-count":9,"title":["What Is the Optimal Dose and Schedule for Dasatinib in Chronic Myeloid Leukemia: Two Case Reports and Review of the Literature"],"prefix":"10.32604","volume":"23","author":[{"given":"Caroline","family":"Jamison","sequence":"first","affiliation":[{"name":"University of Nebraska Medical Center College of Pharmacy, Omaha, NE, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mete","family":"Eren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dron","family":"Gauchan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Ramaekers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Norvell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Sitki","family":"Copur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17807","reference":[{"key":"b1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"b2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00277-005-1039-z","article-title":"Chronic myeloid leukemia: A model for oncology","volume":"84","year":"2005","journal-title":"Ann. Hematol."},{"key":"b3","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4065\/81.7.973","article-title":"Chronic myeloid leukemia: Diagnosis and treatment","volume":"81","year":"2006","journal-title":"Mayo Clin. Proc."},{"key":"b4","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","year":"2006","journal-title":"Cancer Res."},{"key":"b5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1358\/dot.2007.43.1.1050791","article-title":"Dasatinib","volume":"43","year":"2007","journal-title":"Drugs Today (Barc)."},{"key":"b6","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","year":"2007","journal-title":"Blood"},{"key":"b7","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"b8","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib resistant and intolerant chronic phase chronic myeloid leukemia","volume":"26","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"b9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-8722-2-10","article-title":"New dosing schedules of dasatinib for CML and adverse event management","volume":"2","year":"2009","journal-title":"J Hematol. Oncol."},{"key":"b10","first-page":"155","article-title":"Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy","volume":"4","year":"2010","journal-title":"Clin. Med. Insights Oncol."},{"key":"b11","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/ajh.21871","article-title":"Dasatinib even at low doses is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter prospective study on 114 patients","volume":"85","year":"2010","journal-title":"Am. J. Hematol."},{"key":"b12","article-title":"Low-dose dasatinib as front-line therapy for elderly patients with CML","year":"2010","journal-title":"ASH Meeting, Abstract 2293"},{"key":"b13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00277-013-1769-2","article-title":"Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib","volume":"92","year":"2013","journal-title":"Ann. Hematol."},{"issue":"22","key":"b14","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia the ADAGIO study","volume":"113","year":"2009","journal-title":"Blood"},{"issue":"14","key":"b15","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"b16","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/blood.V98.9.2808","article-title":"Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the thyrosine kinase inhibitor STI571","volume":"98","year":"2001","journal-title":"Blood"},{"key":"b17","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1182\/blood-2007-10-113969","article-title":"Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis","volume":"114","year":"2009","journal-title":"Blood"},{"key":"b18","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2008.11.001","article-title":"Transient potent BCRABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis","volume":"14","year":"2008","journal-title":"Cancer Cell"},{"key":"b19","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","article-title":"Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-Month median follow-up","volume":"113","year":"2009","journal-title":"Blood"},{"key":"b20","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"b21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/1078-0432.CCR-07-4175","article-title":"Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate","volume":"14","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"b22","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","year":"2005","journal-title":"Cancer Res."},{"key":"b23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/jnci\/91.2.163","article-title":"In vivo eradication of human BCR\/ABL-positive leukemia cells with an ABL kinase inhibitor","volume":"91","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"key":"b24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","year":"2004","journal-title":"Science"},{"key":"b25","article-title":"Dasatinib Daily Dose Optimization Based on Residual Drug Levels Resulted in Reduced Risk of Pleural Effusions and High Molecular Response Rates: Final Results of the Randomized OPTIM Dasatinib Trial","year":"2014","journal-title":"European Hematology Association, Abstract ABSSUB-5297"},{"key":"b26"},{"key":"b27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","year":"2013","journal-title":"Blood"},{"key":"b28","article-title":"Discontinuation of dasatinib in patients with CML who have maintained complete molecular response for at least one year: Results from a prospective discontinuation (DADI) trial","year":"2013","journal-title":"American Society of Hematology Abstract 3998"}],"container-title":["Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.techscience.com\/uploads\/attached\/file\/20240807\/20240807094941_37679.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T21:32:13Z","timestamp":1733520733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v23n1-2\/57563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,21]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1,21]]}},"alternative-id":["0965-0407(20160121)23:1L.1;1-"],"URL":"https:\/\/doi.org\/10.3727\/096504015x14452563485986","relation":{},"ISSN":["0965-0407"],"issn-type":[{"value":"0965-0407","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1,21]]}}}